NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi
NeOnc reported early clinical improvement in the first child treated with investigational intranasal NEO100 under its Compassionate Care program in Abu Dhabi. According to treating physicians, the critically ill three-year-old with an aggressive brain tumor is now breathing without ventilator support and beginning to move his legs after treatment began.
Key figures
- Drug Name
- NEO100 (intranasal perillyl alcohol)
- Program
- Compassionate Care, Abu Dhabi
- Patients treated
- 1
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.